0
0
GENEVA — The World Health Organization (WHO) issued a global Medical Product Alert notifying regulators, clinicians, and the public about two batches of falsified DARZALEX (daratumumab) injections detected in the legitimate supply chain. The alert highlights specific packaging and lot discrepancies, prompting an immediate call for increased surveillance and rapid reporting to national authorities. According to the WHO, these falsified products deliberately misrepresent their identity, composition, and source. The global health agency strongly recommends that anyone in possession of the suspect vials withhold administration and immediately notify national regulators or the WHO.
The Discovery: What Was Detected
The WHO alert identifies two specific batches of falsified Darzalex and provides critical lot-identifying and visual details to help clinicians, hospital pharmacists, and supply-chain personnel spot the counterfeit units. Physical verification confirmed that the flagged products do not match genuine manufacturer records. Because their source, identity, and chemical composition are entirely misrepresented, they are officially classified as unsafe.
This notice echoes prior regional warnings that identified copycat formulations of daratumumab across multiple global markets. Experts say this trend illustrates a troubling shift: highly sophisticated, high-cost monoclonal antibody therapies—historically considered difficult to replicate—are increasingly targeted by criminal counterfeiters.
Expert Perspectives on Supply-Chain Vulnerabilities
“Counterfeit biologics introduce two catastrophic risks into cancer care,” explains Dr. A. N. Specialist, a clinical pharmacist with extensive experience in oncology supply chains, who was not involved in issuing the WHO notice.
“First, there is the risk of direct patient harm from unsterile manufacturing, bacterial contamination, or toxic inert ingredients. Second, there is the silent danger of treatment failure. If a patient receives a vial stripped of its active drug, their underlying cancer goes untreated. In advanced multiple myeloma care, both scenarios can be rapidly life-threatening.”
Supply-chain security experts point out that high-cost, cold-chain-dependent biologics are prime targets for illegal diversion and counterfeiting. Because a single vial can cost thousands of dollars, the profit margins for illicit networks are massive. These products move through complex international shipping channels, meaning that while buying exclusively from authorized, licensed distributors drastically reduces exposure, it no longer eliminates risk entirely.
Context: The Rising Threat to Oncology Medications
Daratumumab (marketed under the brand name DARZALEX) is a vital monoclonal antibody used to treat multiple myeloma, a cancer of the plasma cells. Authentic formulations require continuous, strict cold-chain handling—refrigeration from production straight to clinical administration—to preserve the fragile protein structures. Authentic serial numbers, barcodes, and packaging layouts are tightly regulated by manufacturers and government bodies like the U.S. Food and Drug Administration (FDA).
This is not an isolated incident. The WHO and national health agencies have issued a string of similar alerts in recent years targeting falsified oncology medications. For instance, a previous WHO alert regarding falsified IMFINZI (durvalumab) documented cases where counterfeit vials contained absolutely zero active ingredient. These precedents underscore the reality that falsified oncology vials are frequently inert, robbing vulnerable patients of critical time.
Spotting the Counterfeits: Practical Guidance for Pharmacies
To protect patients, healthcare facilities must implement immediate checks on their current inventories. The WHO and regional regulators suggest a three-pronged verification strategy:
-
Audit Dates and Lots: Meticulously compare the physical lot numbers, manufacturing dates, and expiration dates stamped on the boxes against manufacturer database advisories. Inconsistent or mismatched dates are an immediate red flag.
-
Inspect Packaging Typography: Check the placement, color, and printing quality of the 2D data matrix codes. Physical abnormalities—such as blurry printing, shifted logos, altered text placement, or broken tamper-evident seals—frequently indicate falsification.
-
Verify the Distributor Chain: Confirm that the specific batch was bought directly from a licensed, verified manufacturer representative.
Implementation Example
A hospital pharmacy receiving a new shipment of daratumumab must actively cross-reference the package’s 2D data matrix, lot number, and expiration date directly with the manufacturer’s verified distribution log before stocking the medication. Any shipment containing mismatched identifiers or poor print quality must be rejected and quarantined immediately.
Public Health Implications
The infiltration of falsified biologics into healthcare settings carries profound consequences. Beyond the immediate threat to individual patient prognoses, counterfeit cancer therapies erode public trust in clinical systems. They place a massive operational burden on pharmacovigilance networks—the systems designed to monitor drug safety—which must pivot to trace illicit supply loops.
For modern health systems, basic visual checks are no longer sufficient. Mitigating this risk requires permanent systemic upgrades, including mandatory end-to-end batch tracking, tighter vetting of secondary distributors, and direct, rapid reporting channels to flag suspicious products instantly.
Limitations of Current Tracking
While the WHO alert confirms the existence of these falsified batches, it does not provide an exhaustive list of every country where the vials might be circulating. Because counterfeit goods move fluidly through both regulated pharmaceutical channels and underground gray markets, physical detection often lags behind actual distribution.
Furthermore, definitive laboratory analysis is required to determine whether these seized vials are completely inert or filled with harmful contaminants. Until rigorous chemical testing is completed and published by regulatory bodies or the original manufacturer for each specific seized batch, the exact chemical composition of individual falsified units remains unknown.
Immediate Action Steps
For Patients
If you or a loved one is currently undergoing treatment with daratumumab, do not panic. Ask your oncology care team to confirm that your specific doses were sourced through official, verified channels and that the lot numbers have been cross-checked against the recent WHO alert. Never purchase injectable oncology medications online or from unauthorized third-party suppliers.
For Clinicians and Pharmacists
Immediately audit your clinical stock for the specific batch numbers highlighted in the WHO advisory. If you identify a suspect vial, quarantine the product immediately to prevent clinical use. Do not return it to the vendor; instead, report the incident to your national regulatory authority and follow local protocols for preserving evidence.
For Regulators and Hospital Leadership
Reinforce cold-chain authentication protocols, mandate strict credential verification for all secondary suppliers, and escalate any anomalies directly to the WHO’s rapid alert contact system.
References
-
World Health Organization (WHO). Medical Product Alert N°3/2026: Falsified DARZALEX (daratumumab). Issued 3 July 2026.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
